Maze Therapeutics raises $191 mln
Summary
SAN FRANCISCO, February 28, 2019 – Third Rock Ventures today announced the launch of Maze Therapeutics, a company focused on translating genetic insights into new medicines. • Aaron Gitler, Ph.D., a neuroscientist and genetics expert whose work has focused on understanding the cellular consequences of protein misfolding to suggest potential strategies for therapeutic intervention. He is a professor and vice chair of the Department of Cellular & Molecular Pharmacology at the University of California, San Francisco and investigator at the Howard Hughes Medical Institute. “Maze has assembled an exceptional team who are leaders in their fields and have shaped many aspects of how we think about genetics, biology and drug discovery,” said Robert Nelsen, managing director and co-founder of ARCH Venture Partners. By combining our team’s scientific vision, strategic leadership, operational expertise and innovative deal-making capabilities, we nurture bold ideas that translate into successful business enterprises.